Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

Resistance to gemcitabine is the main challenge of chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Hence, the development of a response signature to gemcitabine is essential for precision therapy of PDAC. However, existing quantitative signatures of gemcitabine are susceptible to batch eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Kaidong, Geng, Yiding, Wang, Linzhu, Xu, Huanhuan, Zou, Min, Li, Yawei, Zhao, Zhangxiang, Chen, Tingting, Xu, Fengyan, Sun, Liang, Wu, Shuliang, Gu, Yunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394232/
https://www.ncbi.nlm.nih.gov/pubmed/35810469
http://dx.doi.org/10.1002/1878-0261.13279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394232/
https://www.ncbi.nlm.nih.gov/pubmed/35810469
http://dx.doi.org/10.1002/1878-0261.13279

Ejemplares similares